Bristol-Myers Squibb Company

- The company plans to take on additional debt in 2024 to finance acquisitions of Karuna and RayzeBio. - Despite new debt, the firm has a strong financial position with $12.6 billion in cash and marketable securities as of the end of 2023. - The company expects to generate strong cash flow from operations ($4.3 billion in Q4 2023). - They plan to repay approximately $10 billion of debt over the next two years to improve leverage. - No mention of new equity fundraising was made in the provided excerpts. - Financing costs related to Mirati acquisition and new acquisitions (Karuna, RayzeBio) will have some dilutive impact on earnings per share. - Detailed updates on completed transactions and related financial impacts will be provided in Q1 2024 reporting.

- The company is actively executing recent deals closed toward the end of last year, focusing on integration. - Business development remains a priority, with continued interest in bolt-on acquisitions, partnerships, and licensing deals that make strategic and financial sense. - Additional debt financing is planned for 2024 to fund acquisitions of Karuna and RayzeBio. - The company plans to repay approximately $10 billion of debt over the next two years to improve leverage. - Investments continue in commercial development, supply capacity (notably for Breyanzi), and pipeline advancements (including Mirati acquisition-related costs). - Operating expenses will increase modestly due to absorbing costs related to acquisitions and efficiency initiatives. - The company aims to maintain operational efficiencies to support growth investments while preserving high productivity.

- 2024 revenue guidance expects low single-digit reported sales increase, reflecting growth in the portfolio excluding foreign exchange impact. - Growth portfolio sales (e.g., Opdivo, newly launched products) are key drivers for 2024 momentum. - Opdivo growth expected at a more modest pace than last year with potential acceleration in the latter half of 2024 from new product launches. - Strong U.S. sales growth anticipated for Eliquis in 2024, driven by market share gains. - Sotyktu is expected to grow in volume and prescriptions through broader payer access and patient conversion from Bridge programs, aiming for ~20,000 prescriptions in Q4 2024. - Reblozyl sales projected to grow, supported by strong U.S. first-line MDS demand and anticipated approvals internationally. - Breyanzi sales expected to grow starting Q2 2024 with improved supply and new indications. - Zeposia reported 72% growth in 2023; demand-driven growth expected to continue in approved indications. - BMS plans to grow its business in 2024, focusing on accelerating growth products and maintaining operational efficiency.

- Bristol Myers Squibb expects revenue to increase in the low single-digit range in 2024, driven by growth in their growth portfolio (e.g., Opdivo, new launches) despite headwinds from legacy products. - They anticipate gross margin around 74%, reflecting sales mix evolution and absence of prior hedging gains. - Operating expenses are expected to rise in the low single-digit range due to Mirati costs and efficiency reallocation. - Operating margin target remains at least 37%, focusing on operational efficiencies while investing for growth. - Other income & expense (OI&E) projected at ~$250 million income, including PD-1 royalty and Mirati financing costs. - Tax rate guidance is around 17.5%, higher due to nonrecurring items and Pillar 2 impacts. - Non-GAAP EPS guidance is $7.10 to $7.40 for 2024, excluding pending transactions and associated dilution from Karuna and RayzeBio acquisitions. - Long-term growth and sustainable top-tier returns are expected late in the decade, especially post-2026 with new product launches and pipeline maturation.

- For Sotyktu, the company is focused on driving demand and securing broader access to convert patients from Bridge to commercial prescriptions. - Q3 saw about 40% net sales increase excluding clinical trial orders; the plan is to roughly double paid prescriptions to around 20,000 in Q4. - Conversion from Bridge to commercial takes approximately 2-3 months, with ongoing progress as expected. - For Eliquis, patient mix is skewed toward Medicare; pricing changes under IRA expected to improve patient affordability but limited portfolio impact in 2024. - The company expects continued strong performance and growth for Eliquis through 2025. - Negotiations with payers for Sotyktu access ongoing; currently, 65 million lives covered via CVS, ESI, and Cigna in one-step position. - Additional new product launches like Augtyro and cell therapies (Breyanzi) are expected to expand order intake and sales momentum in 2024.